Abstract
Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a major role in the regulation of lipoprotein metabolism, mostly through control of low-density lipoprotein receptor degradation. Depletion of cellular cholesterol causes a compensatory increase in plasma PCSK9 levels, which can diminish the cholesterol-lowering power of statins and may lead to the overproduction of intestinal lipoproteins, mainly thorough the up regulation of microsomal triglyceride transfer protein and the Niemann-Pick C1-like 1 protein, the target of ezetimibe. Thus, ezetimibe therapy may counter this unwanted effect of statins, providing an additional theoretical rationale for combining the effect of ezetimibe on intestinal cholesterol absorption and that of statins on cholesterol synthesis.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 23-26 |
| Number of pages | 4 |
| Journal | Atherosclerosis Supplements |
| Volume | 17 |
| DOIs | |
| State | Published - Feb 1 2015 |
| Externally published | Yes |
Fingerprint
Keywords
- Ezetimibe
- LDL receptor
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Internal Medicine
- Medicine(all)
Cite this
The role of PCSK9 in intestinal lipoprotein metabolism : Synergism of statin and ezetimibe. / Fazio, Sergio.
In: Atherosclerosis Supplements, Vol. 17, 01.02.2015, p. 23-26.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The role of PCSK9 in intestinal lipoprotein metabolism
T2 - Synergism of statin and ezetimibe
AU - Fazio, Sergio
PY - 2015/2/1
Y1 - 2015/2/1
N2 - Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a major role in the regulation of lipoprotein metabolism, mostly through control of low-density lipoprotein receptor degradation. Depletion of cellular cholesterol causes a compensatory increase in plasma PCSK9 levels, which can diminish the cholesterol-lowering power of statins and may lead to the overproduction of intestinal lipoproteins, mainly thorough the up regulation of microsomal triglyceride transfer protein and the Niemann-Pick C1-like 1 protein, the target of ezetimibe. Thus, ezetimibe therapy may counter this unwanted effect of statins, providing an additional theoretical rationale for combining the effect of ezetimibe on intestinal cholesterol absorption and that of statins on cholesterol synthesis.
AB - Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a major role in the regulation of lipoprotein metabolism, mostly through control of low-density lipoprotein receptor degradation. Depletion of cellular cholesterol causes a compensatory increase in plasma PCSK9 levels, which can diminish the cholesterol-lowering power of statins and may lead to the overproduction of intestinal lipoproteins, mainly thorough the up regulation of microsomal triglyceride transfer protein and the Niemann-Pick C1-like 1 protein, the target of ezetimibe. Thus, ezetimibe therapy may counter this unwanted effect of statins, providing an additional theoretical rationale for combining the effect of ezetimibe on intestinal cholesterol absorption and that of statins on cholesterol synthesis.
KW - Ezetimibe
KW - LDL receptor
UR - http://www.scopus.com/inward/record.url?scp=84924943883&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84924943883&partnerID=8YFLogxK
U2 - 10.1016/S1567-5688(15)50006-8
DO - 10.1016/S1567-5688(15)50006-8
M3 - Article
VL - 17
SP - 23
EP - 26
JO - Atherosclerosis Supplements
JF - Atherosclerosis Supplements
SN - 1567-5688
ER -